

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4526157

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PHENEX PHARMACEUTICALS AG	05/22/2017
RECEIVING PARTY DATA	
Name:	GILEAD SCIENCES, INC.
Street Address:	333 LAKESIDE DRIVE
City:	FOSTER CITY
State/Country:	CALIFORNIA
Postal Code:	94404
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	15618666
PCT Number:	US2017036727
CORRESPONDENCE DATA	
Fax Number:	(650)522-5575
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6505743000
Email:	david.castro@gilead.com
Correspondent Name:	GILEAD SCIENCES, INC.
Address Line 1:	333 LAKESIDE DRIVE
Address Line 4:	FOSTER CITY, CALIFORNIA 94404
ATTORNEY DOCKET NUMBER:	1165.PC-PF
NAME OF SUBMITTER:	KEVIN J. CAPPS
SIGNATURE:	/Kevin J. Capps, Reg. No. 67,911/
DATE SIGNED:	07/28/2017
Total Attachments: 2	
source=1165.PC-PF Assignment - Phenex to GSI#page1.tif	
source=1165.PC-PF Assignment - Phenex to GSI#page2.tif	

Assignment

For valuable consideration, we,

Full Name of Assignor	State of Incorporation	Business Address
PHENEX PHARMACEUTICALS AG	a German Company	Donnersbergweg 1, 67059, Ludwigshafen, Germany

hereby assign to

Full Name of Assignee	State of Incorporation	Business Address
Gilead Sciences, Inc.	Delaware	333 Lakeside Drive Foster City, CA 94404

and to its successors and assigns (collectively hereinafter called "the Assignee"), our entire right, title, and interest throughout the world in the inventions and improvements which are subject of one or more applications for United States Patent. Where this Assignment is not filed concurrently with the application, the following identifying information may be added after execution, identified as:

Title of Application	Filing Date	US / PCT Serial Number
FXR (NR1H4) MODULATING COMPOUNDS	06/09/2017	15/618,666
FXR (NR1H4) MODULATING COMPOUNDS	06/09/2017	US2017/036727

This assignment includes said application, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment also includes the right to sue for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein, or provisional rights from any patent applications listed herein.

ASSIGNOR

Claus Kromer
For PHENEX PHARMACEUTICALS AG

May 22, 2017
Date

Representative Name: Claus Kromer

Representative Title: CEO

Witness

Christian Gege
Signature

22 May '17
Date

Christian Gege
Printed Name

ASSIGNEE

J. Elin Hartum
For GILEAD SCIENCES, INC.

5/26/17
Date

Representative Name: J. Elin Hartum

Representative Title: Associate General Counsel, Intellectual Property
Senior Director

Witness

David Castro
Signature

5/26/2017
Date

David Castro
Printed Name